It Is Clear Who Should Take Provenge And Who Should Not

Provenge, despite its demonstrated survival advantage continues to be knocked as a viable treatment for men with castrate resistant prostate cancer. Why is this the case? First,  Provenge does not affect the PSA. Most men will continue to see their PSA rise, as well as their disease progress based on scans, while they take the treatment. Remember, the total treatment time is one month long. Many of our other treatments do affect the PSA, so many men believe that Provenge is nothing more than a placebo. However, I have been saying that not all men are in fact candidates for [...]

More On The Efficacy Of Sipuleucel-T (Provenge) – It Works

Despite its approval five years ago sipuleucel-T (Provenge) remains one of the most controversial treatments available for men with castrate resistant metastatic prostate cancer (mCRPC). Provenge has its advocates (Full Disclosure- I am) and it has many detractors. The detractors argue that it doesn’t work and they hang their hat on the argument that it doesn’t affect the PSA nor disease progression, which is true. Additionally, there was an earlier, now debunked, argument that there was fraud involved in the phase 3 IMPACT trial that derived the data that led to Provenge’s being approved by the FDA. Since Provenge’s approval [...]

The Twists and Turns For Provenge

It was announced today that preliminary results from the Phase II STAND trial demonstrates continued and what is described as a robust immune response with Provenge (sipuleucel-T) that continues two years after completing treatment in men with biochemically-recurrent prostate cancer (BRPC). This finding, along with data from the ongoing Phase IV registry PROCEED trial, are being presented at the 2015 Genitourinary Cancers Symposium (ASCO GU) conference. The STAND study is a randomized, Phase II trial that consisted of two patient study groups designed to eventually allow the possible expansion of the FDA approval for Provenge to men who are still [...]

*Provenge to Survive Dendreon’s Bankruptcy – Welcome Valeant to the Prostate Cancer Community

Dendreon, the manufacture of the only FDA approved immunologic therapy for prostate cancer had been burdened with significant debt. The debt came from their R&D of Provenge, their seeking FDA approval and the construction of three manufacturing plants to produce the treatment. Sadly, the company was unable to get its income ahead of its debt burden and was forced to seek bankruptcy protection. Dendreon was put up for sale by public auction supervised by the U.S. Bankruptcy court. It was announced yesterday that the bidding process has been completed and another pharmaceutical company, Valeant will acquire the rights to Dendreon’s [...]

By | February 11th, 2015|immunotherapy, Provenge, Uncategorized, vaccines|2 Comments
スーパーコピーブランド ロレックススーパーコピー オメガスーパーコピー ブルガリスーパーコピー ブライトリングスーパーコピー カルティエスーパーコピー シャネル時計コピー IWCスーパーコピー フランクミュラースーパーコピー パネライスーパーコピー タグホイヤースーパーコピー ウブロスーパーコピー ガガミラノスーパーコピー ルイヴィトンスーパーコピー シャネルスーパーコピー エルメススーパーコピー グッチスーパーコピー ボッテガヴェネタスーパーコピー プラダスーパーコピー セリーヌスーパーコピー ロレックススーパーコピー ウブロスーパーコピー